Recently, new study results were published in a research project at St. George's University of London in collaboration with the Dove Clinic. Dr. Julian Kenyon, dr. Wai Liu and Angus Dalleish demonstrate a reduction in the size of ependymomas, both in childhood (pediatric) and adults, through the medical use of cannabidiol.
Ependymomas are defined as certain types of tumors that make up about 5 to 10% of all brain tumors (gliomas). In children, they are the third most common cancer of the central nervous system. As ependymomas of the cerebrum, they appear at any age, while in the posterior fossa they occur mainly in childhood, and in the spinal cord more in adulthood.
Strong decline of tumor cells
A number of case studies of cancer patients were examined, including brain tumor patients. These were administered pharmaceutical grade quality oil based on a synthetic form of CBD. Data were collected and evaluated over four years as part of the treatment of 119 cancer patients at the Dove Clinic. In 92 percent of cases, CBD medication was seen to improve upon repeated brain scans. Either in the form of a reduction of the tumor cells that cause metastases (circulating tumor cells), or in the form of a reduction in tumor size. However, in brain tumors of adult patients who had lost their size due to CBD, the tumor continued to grow after discontinuation of cannabidiol, which then resumed treatment with the drug. According to the researchers, this study should not be entitled to comprehensive findings. It should rather be an impetus for further investigations, which are undoubtedly justified by the results. If convincing evidence is provided, pharmaceutical grade CBD oil can be made more widely available and cheaper, researchers hope. In the research on cannabis as a medicine, and on the therapeutic use of CBD in particular, there is still a lot of work to be done to understand which type of CBD oil is most effective and in which dose it can best produce the best effect , The many synergy effects with other treatment measures need to be further explored, as well as the effects of diet and lifestyle habits.
Increased chances of survival
In another study conducted by British biopharmaceutical company GW Pharmaceuticals, cannabis (1: 1) agents were administered to one group of brain tumor patients, one to another. Both were given in addition to the respective standard therapy in patients with particularly poor survival prognoses (the patients had relapsing glioblastoma multiforme, called GBM for short). While almost half of the patients in the placebo group did not survive the following year (47 percent), the drug group had a survival rate of 83 percent over the same period. On average, one patient survived the drug group for 550 days and one member of the placebo group only 369.
No "do-it-yourself" medicine
The cautionary note, which I already pronounce for less severe illnesses, is all the more important in the case of cancer and similarly serious illnesses. If you have a bad illness, first of all you should consult the specialist for his diagnosis. In the case of illness, it should be refrained from experimenting on its own with any CBD oils around. The study's leaders expressly point out the differences in the qualities of various oils, so it is by no means advisable to self-medicate without consultation with the doctor.


GLASMANN, Dieter Klaus. CBD zur Behandlung von Hirntumoren. 1 [online]. 5 Oct, 2018]. Dostupné z: https://www.hanf-magazin.com/medizin/cannabinoide/cbd-in-der-medizin/cbd-zur-behandlung-von-hirntumoren/